Published in AIDS Weekly, October 2nd, 2006
"A novel class of tricyclic HIV integrase inhibitors were designed based on conformational analysis of 1,6-naphthyridine carboxamide compound L-870810 and docking the designed inhibitor into the active site of our integrase enzyme model," scientists in the United States report.
According to H.L. Jin and colleagues at Gilead Sciences Inc., "The efficient syntheses of pyrroloquinoline tricyclic analogs are described."
"The SAR studies resulted in the identification of a lead compound that is more potent and more soluble than L-870810," concluded...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.